ISSN: 2161-1149 (Printed)
+44-77-2385-9429
BioReg (Austrian Registry for Biologicals, Biosimilars and tsDMARDs in Rheumatology); Vienna, Austria
Dr Franz St. Singer is a distinguished expert and author who has published several articles on Rheumatology, works in the Department of Austrian Registry for Biologicals, Biosimilars and tsDMARDs in Rheumatology, Austria.
Research Article
Januskinase Inhibitors to Treat Rheumatoid Arthritis: Real World Data Match Clinical Trial Results. An Evaluation by BioReg, the Austrian Registry for Biologicals, Biosimilars, and Targeted Synthetic DMARDS in the Treatment of Inflammatory Rheumatic
Author(s): Burkhard F. Leeb*, Peter Spellitz, Gabriele Eichbauer-Sturm, Manfred Herold, Miriam Stetter, Rudolf Puchner, Franz St. Singer and Ruth Fritsch-Stork
Background: Whether the safety and efficacy of Januskinase Inhibitors (JAKis) in daily routine treatment of Rheumatoid Arthritis (RA) match the respective clinical trial results is of crucial clinical interest, however, growing, but still limited corresponding evidence is available.
Patients and methods: Data, including adverse events, disease activity scores, patient-related outcomes, and response as well as persistence rates, of all RA patients receiving JAKi treatment registered in the BioReg database were retrieved. The results were described according to those of pivotal clinical trials of JAKis. Analyses were performed using descriptive statistics, such as mean value comparisons, and by drawing patient trajectories.
Results: One-hundred-and twenty-two patients (mean age 64 years; 83.9% female, 60.5% Rheumatoi.. View More»
DOI:
10.35248/2161-1149.21.11.288